Implicit in the decisions regarding initiation or continuation of any antiplatelet agent is the trade-off between thrombosis and bleeding. The well-documented clinical benefits of antiplatelet agentsreduced rates of myocardial infarction (MI), stroke, or cardiovascular death-come at a cost of increased bleeding risk. These bleeding events correlate with subsequent death in both acute coronary syndrome (ACS) 4 and stable atherosclerotic cardiovascular disease. 5 The competing risks of ischaemia and bleeding are well illustrated by the examples of bivalirudin vs. heparin and glycoprotein 2b/3a inhibitors, 6 prasugrel and ticagrelor vs. clopidogrel, 7, 8 and, in particular, the oral protease-activated-receptor (PAR) 1 antagonist, vorapaxar. When added as secondary prevention in stable patients with atherosclerotic disease, vorapaxar significantly reduced the composite primary endpoint of cardiovascular death, MI, or stroke, but at the cost of more moderate or severe bleeding events, including intracranial bleeding. 9 Similarly, in the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, 10 there was a significant reduction in the secondary composite endpoint of cardiovascular death, MI, or stroke in the vorapaxar arm, but the trial was stopped early by the data safety monitoring committee due to an increased rate of moderate to severe bleeding, including intracranial haemorrhage, with vorapaxar.
10
Balancing cardiovascular benefit vs. bleeding risk, and thus choosing the appropriate agent at the appropriate time with the appropriate dose for the appropriate duration, remains challenging. In addition to the trial-specific differences that prevent easy drug-drug comparisons, the simple task of quantifying risk based on the relative importance of the two clinical event types (ischaemia vs. bleeding) is, at best, imprecise. Simply asked, is bleeding equivalent to an MI or stroke? Moreover, what bleeding threshold (minor, major, moderate, severe, intracranial) should be used? Also there is no universally accepted definition for composite endpoints such as 'net clinical benefit' or 'net adverse clinical events (NACE)'. Should these composites include just MI or also urgent revascularization? What severity of bleed should be included? Clarity in terms of the subsequent risk following different types of clinical events would allow a more complete appraisal of risks and benefits.
In this issue, Valgimigli and colleagues 11 assess the strength of the association of MI or bleeding with all-cause mortality in the TRACER trial based on the clinical scenario and the severity of the bleeding event. In this post-hoc analysis, bleeding events were classified according to the Bleeding Academic Research Consortium (BARC) criteria. 12 After multivariable analysis including MI and bleeding as timedependent covariates, the interval development >30 days after index ACS, BARC 2 (overt, actionable) or BARC 3 (severe) bleeding, was associated with an increased risk of all-cause mortality. Both MI and BARC 3 bleeding were associated with more than a five-fold increased risk of death, whereas the risk associated with BARC 2 bleeding was less than a two-fold increase [hazard ratio (HR) 1.77], or about one-third of the associated risk compared with MI. There was no association between BARC 1 bleeds (not actionable) and mortality. Moreover, there was heterogeneity of risk across the subcategories of BARC 3 bleeding. BARC 3a bleeds (n = 164) (haemoglobin drop of 3-5 g/dL or any transfusion) had the weakest association with mortality (HR 2.33) while BARC 3b bleeds (n = 125) (haemoglobin drop >5 g/dL, requiring vasopressors, surgical intervention, or due to cardiac tamponade) were similar to MI (HR 4.51). Though rare, the BARC 3c bleeds (n = 57) (intracranial or Unfortunately, the data presented here are neither designed nor able to answer the central clinical question-how to predict which patients will derive a net clinical benefit of ischaemic event reduction and which are most likely to suffer intracranial bleeding. The most recent American College of Cardiology/American Heart Association guidelines for dual antiplatelet therapy (DAPT) highlight the difficulty in assigning risk and suggest the DAPT score as one possible tool to help clinicians balance these competing risks. [1] [2] [3] 13 However, the DAPT score combines moderate and severe bleeding events, and therefore may 'overestimate' the implications of less serious, reversible bleeding events. It is additionally important to take into account the absolute event rate and not just the relative risk associated with each type of event.
Of the 500 deaths occurring after 30 days, only 275 were preceded by either MI or bleeding, the events of interest for the current analysis. While the relative risk of death with BARC 3c bleeding was many times that for MI, these events were rare, occurring in only 57 patients as compared with 718 MIs. The discordance between absolute vs. relative risk differences further supports the strategy of MI prevention as the most effective method to reduce the greatest number of deaths. (Figure 1 ) There are also implications for clinical trials. While the TIMI and GUSTO scoring systems are widely used in clinical research and allow for direct comparison with other trials, neither specifically isolates intracranial bleeding. 12 As such, the importance of this particular event, and the central message of avoiding irreparable harm, would have been missed without application of the more nuanced BARC classification. Moreover, defining NACE should only be done when combining events that carry similar clinical implications. 14 There are important limitations to this analysis. This is an 'endpoint-endpoint' comparison and, despite multivariable modelling using a time-varying covariate, residual confounding and bias certainly remain. In addition, there is no information on the size of infarct, a well-known risk predictor that would have provided a more sensitive evaluation of MI risk. 15 In summary, Valgimigli et al. have used data from the TRACER trial of vorapaxar in ACS to take on the long-standing challenge of balancing ischaemic and bleeding events with antiplatelet therapy in highrisk patients. They have added to our understanding of the relationship between MI or bleeding and all-cause mortality, shown a stronger association between MI and subsequent mortality than is present for most types of bleeding, and made a cogent argument for regular, explicit reporting of central nervous system haemorrhage separate from other major bleeding events. In so doing, they have demonstrated the primacy of irreversible tissue injury relative to uncomplicated bleeding and given testament to the philosophy 'first, do no (irreparable) harm.'
